Pacific Biosciences of California, Inc. Inventory Write-down
Pacific Biosciences of California, Inc. (PACB) reported Inventory Write-down of $1.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-08-06
- Pacific Biosciences of California, Inc. inventory write-down for the quarter ending 2026-06-30 was $1.36M, a 54.36% increase year-over-year.
- Pacific Biosciences of California, Inc. inventory write-down for the quarter ending 2026-03-31 was $54.00K, a 99.29% decline year-over-year.
- Pacific Biosciences of California, Inc. inventory write-down for the quarter ending 2025-12-31 was -$200.00K, a 122.15% decline year-over-year.
- Pacific Biosciences of California, Inc. inventory write-down for the quarter ending 2025-09-30 was $1.23M.
- Pacific Biosciences of California, Inc. inventory write-down for fiscal 2025 was $9.57M, a 107.19% increase from fiscal 2024.
- Pacific Biosciences of California, Inc. inventory write-down for fiscal 2024 was $4.62M, a 56.37% decline from fiscal 2023.
- Pacific Biosciences of California, Inc. inventory write-down for fiscal 2023 was $10.58M, a 75.61% increase from fiscal 2022.
- Pacific Biosciences of California, Inc. inventory write-down for fiscal 2022 was $6.03M, a 788.94% increase from fiscal 2021.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.42M 10-Q · filed 2026-08-06 | $1.22M derived: sum of 3 quarters · filed 2026-08-06 | $2.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $54.00K 10-Q · filed 2026-05-08 | -$146.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.08M derived: sum of 3 quarters · filed 2026-05-08 | $1.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.03M derived: sum of 2 quarters · filed 2026-02-25 | $1.91M derived: sum of 3 quarters · filed 2026-08-06 | $9.57M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.11M derived: sum of 2 quarters · filed 2026-08-06 | $9.77M 10-Q · filed 2025-11-06 | $10.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $883.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $8.54M 10-Q · filed 2026-08-06 | $9.45M derived: sum of 3 quarters · filed 2026-08-06 | $9.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $7.66M 10-Q · filed 2026-05-08 | $8.56M derived: sum of 2 quarters · filed 2026-05-08 | $8.36M derived: sum of 3 quarters · filed 2026-05-08 | $12.27M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $903.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $696.00K derived: sum of 2 quarters · filed 2026-02-25 | $4.62M derived: sum of 3 quarters · filed 2026-02-25 | $4.62M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$207.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.71M derived: sum of 2 quarters · filed 2025-11-06 | $3.71M 10-Q · filed 2025-11-06 | $9.61M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $3.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.92M 10-Q · filed 2025-08-07 | $9.81M derived: sum of 3 quarters · filed 2026-02-25 | $10.21M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $3.00K 10-Q · filed 2025-05-12 | $5.90M derived: sum of 2 quarters · filed 2026-02-25 | $6.29M derived: sum of 3 quarters · filed 2026-02-25 | $7.07M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $5.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.29M derived: sum of 2 quarters · filed 2026-02-25 | $7.06M derived: sum of 3 quarters · filed 2026-02-25 | $10.58M 10-K · filed 2026-02-25 |
| 2023-09-30 | $396.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.17M derived: sum of 2 quarters · filed 2024-11-12 | $4.69M 10-Q · filed 2024-11-12 | $8.05M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $774.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $4.29M 10-Q · filed 2024-08-09 | $7.66M derived: sum of 3 quarters · filed 2025-03-17 | $8.53M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $3.52M 10-Q · filed 2024-05-09 | $6.88M derived: sum of 2 quarters · filed 2025-03-17 | $7.76M derived: sum of 3 quarters · filed 2025-03-17 | $9.16M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $4.24M derived: sum of 2 quarters · filed 2025-03-17 | $5.64M derived: sum of 3 quarters · filed 2025-03-17 | $6.03M 10-K · filed 2025-03-17 |
| 2022-09-30 | $878.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $2.28M derived: sum of 2 quarters · filed 2023-11-03 | $2.67M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $1.79M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $386.00K 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $678.00K 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $527.00K 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |